Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database

Abstract Objectives This study was conducted to assess changes in the real‐world treatment of atopic dermatitis (AD) in Japan. Methods Patients from the JMDC Claims Database with ≥1 confirmed diagnosis of AD, an identifiable medical care start date for AD, and ≥2 AD–related treatments on separate da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kazumasa Kamei, Hidehisa Saeki, Takanori Tsuchiya, Tomohiro Hirose, Eduardo Campos‐Alberto, Fumihiro Matsumoto, Noritoshi Yoshii, Shinichi Imafuku
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	atopic dermatitis database healthcare costs Japan therapeutics Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/53e494470fe44ec3b6417c0b5c1889cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53e494470fe44ec3b6417c0b5c1889cb
record_format	dspace
spelling	oai:doaj.org-article:53e494470fe44ec3b6417c0b5c1889cb2021-11-08T15:10:52ZReal‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database2574-459310.1002/cia2.12180https://doaj.org/article/53e494470fe44ec3b6417c0b5c1889cb2021-10-01T00:00:00Zhttps://doi.org/10.1002/cia2.12180https://doaj.org/toc/2574-4593Abstract Objectives This study was conducted to assess changes in the real‐world treatment of atopic dermatitis (AD) in Japan. Methods Patients from the JMDC Claims Database with ≥1 confirmed diagnosis of AD, an identifiable medical care start date for AD, and ≥2 AD–related treatments on separate dates between January 1, 2005, and May 31, 2019, were included; data were analyzed on a yearly basis. Results In total, 411,102 patients were included. The average age of patients increased from 12.0 to 18.8 years between 2005 and 2017. In any given year, the prevalence of AD was highest in patients aged <2 years and lowest in patients aged ≥50 years. Dermatology (65.1%‐69.5% from 2005 to 2017) and clinics (92.3%‐93.4%) were the main department and medical facility, respectively, providing daily medical care for AD. The proportion of patients who were given the thymus and activation‐regulated chemokine test increased from 2008 to 2017 (0.03%‐3.5%). From 2005 to 2017, the proportion of patients who received moisturizer (68.8%‐79.1%), topical calcineurin inhibitors (8.2%‐17.8%), very strong topical corticosteroids (26.0%‐40.6%), strongest topical corticosteroids (3.5%‐7.8%), cyclosporine (0.01%‐0.3%), or phototherapy (0.06%‐1.8%) increased, and the proportion of patients who received topical non‐steroidal anti‐inflammatory drugs (12.0%‐3.1%) decreased. Annual costs for medication associated with AD per person/visit increased between 2005 and 2017; however, the ratio of medication to total cost did not. Conclusions The results of this analysis show that Japanese patients used increasingly potent treatments for AD, and overall AD‐related medication costs increased between 2005 and 2017.Kazumasa KameiHidehisa SaekiTakanori TsuchiyaTomohiro HiroseEduardo Campos‐AlbertoFumihiro MatsumotoNoritoshi YoshiiShinichi ImafukuWileyarticleatopic dermatitisdatabasehealthcare costsJapantherapeuticsDermatologyRL1-803Immunologic diseases. AllergyRC581-607ENJournal of Cutaneous Immunology and Allergy, Vol 4, Iss 5, Pp 109-119 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopic dermatitis database healthcare costs Japan therapeutics Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
spellingShingle	atopic dermatitis database healthcare costs Japan therapeutics Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 Kazumasa Kamei Hidehisa Saeki Takanori Tsuchiya Tomohiro Hirose Eduardo Campos‐Alberto Fumihiro Matsumoto Noritoshi Yoshii Shinichi Imafuku Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
description	Abstract Objectives This study was conducted to assess changes in the real‐world treatment of atopic dermatitis (AD) in Japan. Methods Patients from the JMDC Claims Database with ≥1 confirmed diagnosis of AD, an identifiable medical care start date for AD, and ≥2 AD–related treatments on separate dates between January 1, 2005, and May 31, 2019, were included; data were analyzed on a yearly basis. Results In total, 411,102 patients were included. The average age of patients increased from 12.0 to 18.8 years between 2005 and 2017. In any given year, the prevalence of AD was highest in patients aged <2 years and lowest in patients aged ≥50 years. Dermatology (65.1%‐69.5% from 2005 to 2017) and clinics (92.3%‐93.4%) were the main department and medical facility, respectively, providing daily medical care for AD. The proportion of patients who were given the thymus and activation‐regulated chemokine test increased from 2008 to 2017 (0.03%‐3.5%). From 2005 to 2017, the proportion of patients who received moisturizer (68.8%‐79.1%), topical calcineurin inhibitors (8.2%‐17.8%), very strong topical corticosteroids (26.0%‐40.6%), strongest topical corticosteroids (3.5%‐7.8%), cyclosporine (0.01%‐0.3%), or phototherapy (0.06%‐1.8%) increased, and the proportion of patients who received topical non‐steroidal anti‐inflammatory drugs (12.0%‐3.1%) decreased. Annual costs for medication associated with AD per person/visit increased between 2005 and 2017; however, the ratio of medication to total cost did not. Conclusions The results of this analysis show that Japanese patients used increasingly potent treatments for AD, and overall AD‐related medication costs increased between 2005 and 2017.
format	article
author	Kazumasa Kamei Hidehisa Saeki Takanori Tsuchiya Tomohiro Hirose Eduardo Campos‐Alberto Fumihiro Matsumoto Noritoshi Yoshii Shinichi Imafuku
author_facet	Kazumasa Kamei Hidehisa Saeki Takanori Tsuchiya Tomohiro Hirose Eduardo Campos‐Alberto Fumihiro Matsumoto Noritoshi Yoshii Shinichi Imafuku
author_sort	Kazumasa Kamei
title	Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
title_short	Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
title_full	Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
title_fullStr	Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
title_full_unstemmed	Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
title_sort	real‐world treatment patterns of patients with atopic dermatitis in japan: analysis of the jmdc claims database
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/53e494470fe44ec3b6417c0b5c1889cb
work_keys_str_mv	AT kazumasakamei realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT hidehisasaeki realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT takanoritsuchiya realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT tomohirohirose realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT eduardocamposalberto realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT fumihiromatsumoto realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT noritoshiyoshii realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase AT shinichiimafuku realworldtreatmentpatternsofpatientswithatopicdermatitisinjapananalysisofthejmdcclaimsdatabase
_version_	1718442131592314880

Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database

Ejemplares similares